Schellens and his colleagues were the first to demonstrate that resistance of LS180 colon cancer cells to a specific subset of kinase inhibitors (erlotinib, gefitinib, nilotinib, sorafenib, and vandetanib) relied on a PXR-mediated increase in ABCB1 expression [21]. Here, NR1I2 is linked to colonic neoplasm.